Subjective experience of recovery from schizophrenia-related disorders and atypical antipsychotics

被引:41
作者
Jenkins, JH
Strauss, ME
Carpenter, EA
Miller, D
Floersch, J
Sajatovic, M
机构
[1] Case Western Reserve Univ, Dept Anthropol, Cleveland, OH 44106 USA
[2] Case Western Reserve Univ, Dept Psychiat, Cleveland, OH 44106 USA
[3] Case Western Reserve Univ, Dept Psychol, Cleveland, OH 44106 USA
[4] Case Western Reserve Univ, Mandel Sch Social & Appl Sci, Cleveland, OH 44106 USA
[5] Univ Hosp Cleveland, Cleveland, OH 44106 USA
[6] Case Dept Psychiat, Cleveland, OH USA
关键词
D O I
10.1177/0020764005056986
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Aims: This article investigates the subjective experience of the process of improvement and recovery from the point of view of persons diagnosed (according to research diagnostic criteria) with schizophrenia and schizo-affective disorders. Methods: A community study of persons using psychiatric services was conducted for a sample of ninety subjects taking atypical antipsychotic medications. Sociodemographic data and clinical ratings were collected to complement the qualitatively developed Subjective Experience of Medication Interview (SEMI), which elicits narrative data on everyday activities, medication and treatment, management of symptoms, expectations concerning recovery, stigma, and quality of life. Results: Recovery was observed through: (1) relatively low ratings of psychiatrically observed symptomatology through BPRS scores; (2) the subjective sense among the majority (77.4%) of participants that taking medication plays a critical role in managing symptoms and avoiding hospitalization; and (3) the subjective sense articulated by the vast majority (80%) that they would recover from their illness and that the quality of their lives would improve (70.6%). Conclusion: The overall quality of improvement and recovery is best characterized as an incremental, yet definitively discernable, subjective process.
引用
收藏
页码:211 / 227
页数:17
相关论文
共 69 条
[1]   Emerging roles for novel antipsychotic medications in the treatment of schizophrenia [J].
Andersson, C ;
Chakos, M ;
Mailman, R ;
Lieberman, J .
PSYCHIATRIC CLINICS OF NORTH AMERICA, 1998, 21 (01) :151-+
[2]  
ANDREASEN N C, 1989, British Journal of Psychiatry, V155, P49
[3]  
[Anonymous], 2002, Personal Therapy for Schizophrenia and Related Disorders
[4]  
[Anonymous], QUAL METH HLTH RES O
[5]  
[Anonymous], 1984, CULTURE THEORY ESSAY
[6]  
Awad A. G., 1994, Acta Psychiatrica Scandinavica, V89, P27, DOI 10.1111/j.1600-0447.1994.tb05828.x
[7]   MEASUREMENT OF PSYCHOLOGICAL ANDROGYNY [J].
BEM, SL .
JOURNAL OF CONSULTING AND CLINICAL PSYCHOLOGY, 1974, 42 (02) :155-162
[8]   Clozapine treatment of outpatients with schizophrenia: Outcome and long-term response patterns [J].
Breier, A ;
Buchanan, RW ;
Irish, D ;
Carpenter, WT .
PSYCHIATRIC SERVICES, 2000, 51 (10) :1249-1253
[9]   Health beliefs and compliance with antipsychotic medication [J].
Budd, RJ ;
Hughes, ICT ;
Smith, JA .
BRITISH JOURNAL OF CLINICAL PSYCHOLOGY, 1996, 35 :393-397
[10]  
Burger GK, 1997, J CLIN PSYCHOL, V53, P451, DOI 10.1002/(SICI)1097-4679(199708)53:5<451::AID-JCLP5>3.3.CO